Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Craig Davitt

Physician Assistant Manasquan, NJ Physician Assistant

NPI 1801266523 CMS profile 11211569

2315 Highway 34, Suite D, Manasquan, NJ 08736

Open in the dashboard

General payments

$6,598

362 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Craig Davitt of Manasquan, NJ is reported in the CMS Open Payments database as having received $6,598 across 362 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $927 24
2024 General $5,034 308
2023 General $472 19
2022 General $47 3
2021 General $118 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Craig Davitt
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Craig Davitt were reported at $927. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Craig Davitt Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $118 $132 $37–$438 $132
2022 $47 $155 $48–$522 $149
2023 $472 $167 $52–$557 $160
2024 $5,034 $178 $55–$600 $164
2025 $927 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,151 61 payments
  2. Janssen Biotech, Inc. $1,148 66 payments
  3. Amgen Inc. $806 59 payments
  4. Stryker Corporation $792 12 payments
  5. AstraZeneca Pharmaceuticals LP $540 23 payments
  6. Novartis Pharmaceuticals Corporation $242 14 payments
  7. ANI Pharmaceuticals, Inc. $191 13 payments
  8. Mallinckrodt Hospital Products Inc. $185 13 payments
  9. UCB, Inc. $183 15 payments
  10. E.R. Squibb & Sons, L.L.C. $140 12 payments
  11. Other $1,220 74 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,457 359 payments
  2. Education $141 3 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $886 49 payments
  2. RINVOQ $883 48 payments
  3. MAKO $792 12 payments
  4. SIMPONI ARIA $524 27 payments
  5. SAPHNELO $523 22 payments
  6. ACCOLADE $307 2 payments
  7. TRIATHLON $307 2 payments
  8. Enbrel $257 29 payments
  9. SKYRIZI $256 13 payments
  10. TAVNEOS $255 11 payments
  11. Other $3,321 214 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$342,103

Of which drugs: $232,641

Medicare patients

465

Average age 74

Services billed

48,536

320 women, 145 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 38%
Diabetes 35%
Depression 25%
Osteoporosis 23%
Chronic kidney disease 21%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 Office 54 38,400 $139,100
Injection, denosumab, 1 mg J0897 Office 21 1,320 $26,603
Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 Office 22 2,040 $11,468
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 111 359 $1,765
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 74 892 $692
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 21 34 $31

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $838
$838 — —
TREMFYA
  • Janssen Biotech, Inc. $590
$590 — —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $510
$510 — —
SIMPONI ARIA
  • Janssen Biotech, Inc. $365
$365 — —
TAVNEOS
  • Amgen Inc. $255
$255 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

362 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record